Eyesense
Stage
Corporate Minority | AliveTotal Raised
$8.3MLoading...
Loading...
Eyesense Patents
Eyesense has filed 21 patents.
The 3 most popular patent topics include:
- diabetes
- insulin therapies
- dosage forms

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
1/22/2019 | 6/13/2023 | Drug delivery devices, Dosage forms, Medical equipment, Particle physics facilities, Engine fuel system technology | Grant |
Application Date | 1/22/2019 |
---|---|
Grant Date | 6/13/2023 |
Title | |
Related Topics | Drug delivery devices, Dosage forms, Medical equipment, Particle physics facilities, Engine fuel system technology |
Status | Grant |
Latest Eyesense News
Jul 9, 2013
Wed, 12/01/2011 - 10:16 Fund Links all funds all hedge all etf all open ended all closed ended all ucits all traditional/long all property all private equity by structure by country by city by domicile by administrator by custodian closures launches EyeSense AG, a venture capital-backed developer of novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients, has entered into a strategic partnership with QIAGEN. Capitalising on QIAGEN’s ESE fluorescence-based optical technology and on Eyesense’s glucose sensing technology, the partners intend to develop a new optical measurement technology for blood glucose monitoring in diabetes patients. QIAGEN acquired a minority equity stake in EyeSense, and attained royalty rights for future commercialisation. Both the investment and the partnership are aimed at further expanding the range of applications for the growing segment of point-of-need testing and individualised treatment of patients. Financial details have not been disclosed. EyeSense’s blood glucose monitoring (BGM) approach marks an important step forward in the diabetes field. The Company’s innovative and painless device is based on a non-invasive ophthalmic diagnostic system, and first patient studies have already yielded promising data. The ease of use, robustness, and reliability of the device will empower patients to manage their disease with confidence, and with improved comfort. EyeSense’s technology is poised to introduce a completely new way of self-diagnosis that will be applicable to other therapeutic areas as well. The Company intends to launch the new device in 2013. "The collaboration with QIAGEN is an important validation of EyeSense’s progress to date, and substantially strengthens our development efforts," says Achim Müller, CEO and co-founder of EyeSense AG. "With its leadership in innovative optical measurement systems, QIAGEN is an ideal partner to help us maximize our development and engineering know-how, take our technology to the next level, and put our advanced monitoring devices in the hands of patients at an accelerated pace. " Tags :
Eyesense Frequently Asked Questions (FAQ)
What is Eyesense's latest funding round?
Eyesense's latest funding round is Corporate Minority.
How much did Eyesense raise?
Eyesense raised a total of $8.3M.
Who are the investors of Eyesense?
Investors of Eyesense include QIAGEN, Novartis Venture Funds, EQT Life Sciences, Private Life Biomed AG, Alstertor Private Life and 3 more.
Who are Eyesense's competitors?
Competitors of Eyesense include Pacific Diabetes Technologies, Innara Health, Intuity Medical, Senseonics, Propeller Health and 7 more.
Loading...
Compare Eyesense to Competitors
Third Eye Diagnostics is a company focused on the development of non-invasive technologies for the evaluation of intracranial pressure, operating in the medical technology sector. The company's main product is a non-invasive intracranial pressure monitor that gathers information from the patient's eye, providing a single point reading of intracranial pressure, which can be used for diagnosing and monitoring conditions like traumatic brain injuries, stroke, and glaucoma. The company primarily sells to sectors such as hospital Neuro-ICUs, emergency rooms, surgical suites, medical transport vehicles, general practitioner offices, and sports events. It is based in Bethlehem, Pennsylvania.
Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr
MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.
Neuro Diagnostic Devices, also known as NeuroDx Development, is a medical device company operating in the healthcare sector. The company's primary product is a non-invasive device used to detect fluid flow in implanted cerebrospinal fluid (CSF) shunts, aiding in the diagnosis and treatment of neurosurgical conditions. The company primarily serves the healthcare industry, specifically the neurosurgical market. It is based in Yardley, Pennsylvania.

Innara Health develops feeding technologies to measure and treat infants, children, and adults that struggle with suck, swallow, and breathe coordination. The company offers a neonatal technology that assesses and develops non-nutritive suck skills for newborns and infants born prematurely. Innara Health was formerly known as KC BioMediX. The company was founded in 2006 and is based in Olathe, Kansas.
Infrascan is a medical device company that focuses on the development, commercialization, and distribution of portable brain scanners in the healthcare industry. The company's main product is a handheld diagnostic device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, aiding in the identification of those who would most benefit from immediate referral to a CT scan and neurosurgical intervention. The company primarily serves sectors such as emergency rooms, intensive care units, military field hospitals, sports medicine, ambulance services, and remote locations. It is based in Philadelphia, Pennsylvania.
Loading...